Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Takes Unapproved Quinine Drugs Off The Market

This article was originally published in The Pink Sheet Daily

Executive Summary

Physicians warned against prescribing for leg cramps, which accounts for 70% of usage.

You may also be interested in...



Mutual Launches Malaria Drug Qualaquin, Warns Of Unapproved Competitors

Company hopes to get FDA to remove other quinine products from the market.

FDA Kicks Off Unapproved Drug Crack-Down With Carbinoxamine Enforcement

FDA is focusing initially on drugs containing the antihistamine carbinoxamine because of safety concerns in children.

Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says

Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS063523

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel